KOL | Yukako OgiMedicine Division, Nippon Boehringer Ingelheim Co, Ltd., Tokyo, Japan |
KOL Resume for Yukako Ogi
| Year | |
|---|---|
| 2020 | Medicine Division, Nippon Boehringer Ingelheim Co, Ltd., Tokyo, Japan |
Prominent publications by Yukako Ogi
INTRODUCTION: Idarucizumab, a monoclonal antibody fragment, was developed to reverse the anticoagulant effect of dabigatran, and it was approved in Japan in September 2016. An all-case post-marketing surveillance is ongoing to collect data in Japanese patients treated with idarucizumab who had serious bleeding (Group A) or required an urgent procedure (Group B).
METHODS: The primary endpoint was the incidence of adverse drug reactions (ADRs). The secondary endpoint was the maximum extent ...
| Known for Japanese Patients | Idarucizumab Dabigatran |
Key People For Idarucizumab Dabigatran
Yukako Ogi:Expert Impact
Concepts for whichYukako Ogihas direct influence:Idarucizumab dabigatran.
Yukako Ogi:KOL impact
Concepts related to the work of other authors for whichfor which Yukako Ogi has influence:Reversal agents, Severe bleeding, Management atrial fibrillation, Effective hemostasis 95, Patient characteristics dabigatran, Availability idarucizumab, Study 110 bid.
Tools
Is this your profile? Claim your profile Copy URL Embed Link to your profile |